Enspryng

Generic name: Satralizumab
Drug class: Interleukin inhibitors

Usage of Enspryng

Enspryng is a recombinant humanized monoclonal antibody targeting human interleukin-6 (IL-6) receptors.

Enspryng is a prescription medicine used to treat adults with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, chronic autoimmune disease that causes inflammation in the central nervous system. This can lead to damage of the optic nerves, spinal cord, and/or brain.

Enspryng is used only if your body produces antibodies to a protein called aquaporin-4 (AQP4). Your doctor will test you for this antibody.

Enspryng side effects

Stop using this medicine and get emergency medical help if you have signs of an allergic reaction to Enspryng: hives; feeling light-headed; stomach pain, vomiting; difficult breathing; swelling of your face, lips, tongue, or throat.

You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have signs of infection such as:

fever, chills, night sweats;

sore throat. ongoing cough, feeling very tired;

muscle pain;

diarrhea, stomach cramps;

loss of appetite, weight loss;

increased urination, burning when you urinate; or

skin sores, redness, swelling or tenderness.

Common Enspryng side effects may include:

headache, joint pain;

nausea, stomach pain;

feeling tired;

pain in your arms, hands, legs, or feet;

rash; or

cold symptoms such as stuffy nose, runny nose, sneezing, sore throat.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Enspryng

You should not use Enspryng if you are allergic to satralizumab, or if you have an active infection such as:

hepatitis B; or

tuberculosis.

To make sure Enspryng is safe for you, tell your doctor if you have ever had: tuberculosis, if anyone in your household has tuberculosis, or if you have recently traveled to an area where tuberculosis is common.

To make sure Enspryng is safe for you, tell your doctor if you have ever had::

an active or chronic infection;

liver problems, hepatitis B (or if you are a carrier of hepatitis B); or

if you have recently received or are scheduled to receive a vaccine.

Make sure you are current on all vaccines before you begin treatment with Enspryng.

You should not receive a "live" vaccine for at least 4 weeks before using Enspryng. Live vaccines include measles, mumps, rubella (MMR), rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and nasal flu (influenza) vaccine.

You should not receive a "non-live" (sometimes called inactivated) vaccine for at least 2 weeks before using Enspryng. Non-live vaccines include the flu (influenza) shot and injected vaccines for hepatitis A, polio, or rabies.

Tell your doctor if you are pregnant or breastfeeding.

If you use Enspryng while you are pregnant, make sure any doctor caring for your new baby knows that you used this medicine during pregnancy. Being exposed to satralizumab in the womb could affect your baby's vaccination schedule.

Relate drugs

How to use Enspryng

Usual Adult Dose for Neuromyelitis Optica:

120 mg suBCutaneously at Weeks 0, 2, and 4, followed by 120 mg subcutaneously every 4 weeks Use: For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

Warnings

Enspryng affects your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor if you have signs of infection (fever, chills, cough, tiredness, muscle pain, diarrhea, stomach cramps, increased urination, burning when you urinate, skin sores or redness, swelling or tenderness).

Your healthcare provider will check if you have an infection and treat it if needed before you start or continue to take Enspryng.

Your healthcare provider should test you for hepatitis and tuberculosis (TB) before you start taking Enspryng.

What other drugs will affect Enspryng

Other drugs may interact with satralizumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.